MX2020004962A - Preparacion de liberacion controlada. - Google Patents

Preparacion de liberacion controlada.

Info

Publication number
MX2020004962A
MX2020004962A MX2020004962A MX2020004962A MX2020004962A MX 2020004962 A MX2020004962 A MX 2020004962A MX 2020004962 A MX2020004962 A MX 2020004962A MX 2020004962 A MX2020004962 A MX 2020004962A MX 2020004962 A MX2020004962 A MX 2020004962A
Authority
MX
Mexico
Prior art keywords
controlled release
release formulation
diphenylpyradine
butyloxy
isopropylamino
Prior art date
Application number
MX2020004962A
Other languages
English (en)
Inventor
Shouji Furuta
Naoto Hattori
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of MX2020004962A publication Critical patent/MX2020004962A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un objetivo de la presente invención es proporcionar una preparación de liberación controlada que contiene 2-{4-[N- (5,6-difenilpirazin-2-il)-N-isopropilamino]butiloxi}-N- (metilsulfonil)acetamida como un componente activo y que tiene una excelente propiedad de liberación. Una preparación de liberación controlada caracterizada porque contiene 2-{4-[N-(5,6-difenilpirazin-2-il) Nisopropilamino] butiloxi}-N-(metilsulfonil)acetamida, un polímero soluble en agua, un almidón funcional, y una sustancia alcalina, y que tiene un pH de 10 o más.
MX2020004962A 2017-11-16 2018-11-15 Preparacion de liberacion controlada. MX2020004962A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017220777 2017-11-16
PCT/JP2018/042359 WO2019098300A1 (ja) 2017-11-16 2018-11-15 放出制御製剤

Publications (1)

Publication Number Publication Date
MX2020004962A true MX2020004962A (es) 2020-08-27

Family

ID=66539085

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004962A MX2020004962A (es) 2017-11-16 2018-11-15 Preparacion de liberacion controlada.

Country Status (12)

Country Link
US (1) US11382912B2 (es)
EP (1) EP3711763A4 (es)
JP (1) JPWO2019098300A1 (es)
KR (1) KR20200088382A (es)
CN (1) CN111565720A (es)
AR (1) AR113882A1 (es)
AU (1) AU2018369664A1 (es)
BR (1) BR112020008940A2 (es)
CA (1) CA3082009A1 (es)
MX (1) MX2020004962A (es)
TW (1) TW201922230A (es)
WO (1) WO2019098300A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020157730A1 (en) 2019-02-03 2020-08-06 Patel Jayendrakumar Dasharathlal A controlled release pharmaceutical composition of selexipag or it's active metabolite
WO2021153716A1 (en) * 2020-01-31 2021-08-05 Nippon Shinyaku Co., Ltd. Controlled release composition
TWI908789B (zh) * 2020-04-10 2025-12-21 日商日本新藥股份有限公司 固形製劑及其製造方法
EP4337210A4 (en) * 2021-05-11 2025-03-19 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi STABLE PHARMACEUTICAL COMPOSITION CONTAINING SELEXIPAG
CN116459238B (zh) * 2023-05-08 2023-12-05 乐明药业(苏州)有限公司 一种促进氨基葡萄糖持续释放的组合物及应用
WO2025249407A1 (ja) * 2024-05-27 2025-12-04 日本新薬株式会社 セレキシパグ錠剤及びその製造方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62120315A (ja) 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法
JPS63215620A (ja) 1987-03-03 1988-09-08 Nippon Soda Co Ltd 徐放性製剤
JP3744941B2 (ja) 1997-03-14 2006-02-15 東レ株式会社 プロスタグランジンｉ誘導体徐放性製剤
TWI316055B (es) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
JP4959191B2 (ja) 2003-07-11 2012-06-20 旭化成ケミカルズ株式会社 機能性澱粉粉末
US20070048377A1 (en) 2005-08-26 2007-03-01 Ali Rajabi-Siahboomi Drug compositions containing controlled release hypromellose matrices
HRP20201352T1 (hr) 2008-02-28 2020-11-27 Nippon Shinyaku Co., Ltd. Inhibitor fibroze
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
HUE025885T2 (en) 2008-06-23 2016-05-30 Nippon Shinyaku Co Ltd Therapeutic agent for the treatment of spinal constriction
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
SI2289518T1 (sl) 2008-06-23 2017-02-28 Nippon Shinyaku Co., Ltd. Terapevtsko sredstvo za vnetno črevesno bolezen
US8575175B2 (en) 2008-07-23 2013-11-05 Toray Industries, Inc. Therapeutic agent for chronic renal failure
KR20170024165A (ko) 2009-06-26 2017-03-06 니뽄 신야쿠 가부시키가이샤 결정
US8912192B2 (en) 2010-02-12 2014-12-16 Taisho Pharmaceutical Co., Ltd Extended release preparation
JP5960523B2 (ja) 2012-06-29 2016-08-02 旭化成株式会社 加工澱粉と溶出制御剤からなる固形製剤
WO2017029594A1 (en) 2015-08-17 2017-02-23 Dr. Reddy's Laboratories Limited Processes for preparation of selexipag and its amorphous form
US10188648B2 (en) 2015-09-03 2019-01-29 Teva Pharmaceuticals International Gmbh Solid state forms of selexipag
WO2017042731A1 (en) 2015-09-10 2017-03-16 Lupin Limited Amorphous form of selexipag and solid dispersion thereof
EP4331607B1 (en) 2015-12-02 2025-04-30 Nippon Shinyaku Co., Ltd. Solid pharmaceutical composition containing 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide
WO2017121806A1 (en) * 2016-01-15 2017-07-20 Sandoz Ag Pharmaceutical composition of selexipag
WO2018015974A1 (en) 2016-07-20 2018-01-25 Mylan Laboratories Limited Polymorphic forms and amorphous solid dispersion of selexipag
WO2018015975A1 (en) 2016-07-22 2018-01-25 Sun Pharmaceutical Industries Limited Amorphous solid dispersion of selexipag
WO2018022704A1 (en) 2016-07-26 2018-02-01 Teva Pharmaceuticals International Gmbh Crystalline form vi of selexipag
CN107811994B (zh) * 2016-09-12 2020-09-25 江苏艾立康药业股份有限公司 一种西里帕格pH依赖-时滞型结肠靶向微丸及其制备方法

Also Published As

Publication number Publication date
JPWO2019098300A1 (ja) 2020-11-19
TW201922230A (zh) 2019-06-16
CN111565720A (zh) 2020-08-21
KR20200088382A (ko) 2020-07-22
EP3711763A1 (en) 2020-09-23
US20200360373A1 (en) 2020-11-19
AU2018369664A1 (en) 2020-05-21
CA3082009A1 (en) 2019-05-23
AR113882A1 (es) 2020-06-24
EP3711763A4 (en) 2021-08-18
BR112020008940A2 (pt) 2020-10-20
US11382912B2 (en) 2022-07-12
WO2019098300A1 (ja) 2019-05-23

Similar Documents

Publication Publication Date Title
MX2020004962A (es) Preparacion de liberacion controlada.
EP4512399A3 (en) Solid state forms of tafamidis and salts thereof
EP4427588A3 (en) Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
EP4327880A3 (en) Solid state form of ribociclib succinate
EP4516355A3 (en) Stable cannabinoid formulations
SA518391686B1 (ar) {4- [n- (5، 6- داي فينيل بيرازين -2- يل) –n- تركيبة صيدلانية تحتوي على 2- –n- أيزوبروبيل أمينو] بيوتيل أوكسي} (ميثيل سيلفونيل) أسيتاميد
ZA202207729B (en) Solid state form of pyroxasulfone
WO2010111640A3 (en) Anti-influenza formulations and methods
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
NZ732529A (en) Microencapsulated nitrification inhibitor compositions
NZ745210A (en) Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor
NZ608846A (en) Aryloxyurea compound and pest control agent
WO2021094832A8 (en) Heterocyclic nmda antagonists
EA202192388A1 (ru) Составы против микробиоты для чрескожного применения
TW200724166A (en) Wrinkle-improving agent
PH12016502386B1 (en) Oral care compositions
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
MY189371A (en) Agrochemical composition
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
AU2017370226A1 (en) Pharmaceutical composition containing insulin-like growth factor-2 and use thereof
MX2019002234A (es) Compuesto de 1-fenil-3-carbamoil urea y uso del mismo.
IL276069A (en) Using functional calcium carbonate as an active ingredient
MY201786A (en) Liquid herbicidal composition
MX2019002233A (es) Compuesto de fenil urea y uso del mismo.